Sara A. Hurvitz, MD

Sara A. Hurvitz, MD

Breast Medical Oncology
Average rating: 5.0
(64 ratings)  
Accepting new patients
Primary Location
Santa Monica Parkside Cancer Care
2336 Santa Monica Boulevard
Suite 304
Santa Monica, California 90404


Dr. Sara Hurvitz is a medical oncologist who practices in the Santa Monica Parkside location, which houses UCLA Health’s integrative breast cancer practice and high-risk breast cancer clinic. She specializes in the treatment of women with breast cancer, and is involved in designing, implementing and leading national and international clinical trials to test new targeted therapies. She is board certified in internal medicine and medical oncology.

Dr. Hurvitz maintains a robust clinical and translational research portfolio, for which she has won numerous awards over the years, including the Marni Levine Memorial Breast Cancer Research Award in years between 2008 and 2015. She currently leads the Translation Oncology Research Laboratory at UCLA in the preclinical evaluation of novel breast cancer targets.

Dr. Hurvitz earned her medical degree from the University of Southern California School of Medicine. She then completed her internal medicine residency at UCLA, serving as chief resident, followed by her hematology/oncology fellowship at UCLA.

Dr. Hurvitz is an associate professor at the David Geffen School of Medicine at UCLA; medical director of the Jonsson Comprehensive Cancer Center Clinical Research Unit; co-director of the Santa Monica-UCLA Outpatient Oncology Practices; and director of the Breast Cancer Clinical Trials Program at UCLA. She is also a member of the American Society of Clinical Oncology and the American Association of Cancer Research, and is a fellow of the American College of Physicians.




Medical Board Certifications

Medical Oncology, American Board of Internal Medicine, 2006
Internal Medicine, American Board of Internal Medicine, 2002


Hematology/Oncology, UCLA School of Medicine, 2006


Chief Resident, UCLA School of Medicine, 2003
Internal Medicine, UCLA School of Medicine, 2002


Internal Medicine, UCLA School of Medicine, 2000


MD, Keck School of Medicine of USC, 1999


Hospital Affiliations

Ronald Reagan UCLA Medical Center

UCLA Santa Monica Medical Center

Areas of Focus



Dr. Sara Hurvitz is interested in designing, implementing and leading national and international phase I, II, and III (translational) breast cancer clinical trials evaluating novel medicines for the treatment of this disease. She is particularly interested in the development and testing of new targeted therapies for the treatment of breast cancer.

Dr. Hurvitz is also interested in studying the gene expression patterns in a variety of breast cancer populations, and evaluating these patterns to detect new subtypes of breast cancer that may be more accurately targeted by novel therapies.


Link to Dr. Hurvitz's PubMed publications >

  1. Hurvitz SA, Hurvitz CH, Sloninsky L, Sanford MC. Successful treatment with cyclophosphamide of life-threatening diffuse hemangiomatosis involving the liver. Journal of Pediatric Hematology/Oncology 2000;22:527-532. 
  2. Ancheta RG, Lewin H, Said J, Hurvitz SA. Primary dural marginal zone lymphoma in a woman with inflammatory breast cancer. J Clin Oncol. 2008 Jan 10;26(2):326-8.
  3. Hurria A, Wong FL, Villaluna D, Bhatia S, Chung CT, Mortimer J, Hurvitz S, Naeim A.  The Role of Age and Health in Treatment Recommendations for Older Adults with Breast Cancer: The Perspective of Oncologists and Primary Care Providers. J Clin Oncol 2008 Nov 20; 26(33):5386-92.
  4. Betting D, Kafi K, Abdollahi-Fard A, Hurvitz S, Timmerman J.  Sulfhydryl-based tumor antigen-carrier protein conjugates stimulate superior anti-tumor immunity against B cell lymphomas. Journal of Immunology. 2008;181(6):4131-40. PMID: 18768870.
  5. Ansell SM, Hurvitz SA, Koenig P, LaPlant B, Kabat B, Fernando D, Habermann T, Inwards D, Verma M, Yamada R, Erlichman C, Lowy I, Timmerman J. Phase I Study of Ipilimumab (MDX-010), an anti-CTLA-4 monoclonal antibody, in patients with Relapsed and Refractory B-cell non-Hodgkin Lymphoma. Clin Cancer Res 2009;15(20):6446-53. PMID: 19808874
  6. Hurria A, Wong FL, Pal SA, Chung CT, Bhatia S, Mortimer J, Somlo G, Hurvitz S, Villaluna D, Naeim A. Perspectives and Attitudes on the Use of Adjuvant Chemotherapy and Trastuzumab in Older Adults with HER-2 Breast Cancer: A Survey of Oncologists. Oncologist 2009 Sep;14(9):883-90. PMID: 19726455.
  7. Hurvitz SA, Allen HJ, Moroos RL, Chan D, Hagenstad C, Applebaum S, Patel G, Hu EH, Ryba N, Lin LS, Wang H, Glaspy J, Slamon DJ, Kabbinavar F.  A Phase II Trial of Docetaxel With Bevacizumab as First-Line Therapy for HER2-Negative Metastatic Breast Cancer (TORI B01). Clinical Breast Cancer 2010 Aug 1; 10(4):307-12. PMID: 20705564
  8. Andre F, Campone M, O'Regan R, Manlius C, Massacesi C, Sahmoud T, Mukhopadhyay P, Soria JC,  Naughton M, and Hurvitz SA. Phase I Study of Everolimus Plus Weekly Paclitaxel and Trastuzumab in Patients With Metastatic Breast Cancer Pretreated With Trastuzumab. Journal of Clinical Oncology 2010 Dec 1;28(34):5110-5. PMID: 20975068.
  9. Martin M, Roche H, Pinter T, Crown J, Kennedy MJ, Provencher L, Priou F, Eiermann W, Adrover E, Lang I, Ramos M, Latreille J, Jagiełło-Gruszfeld A, Pienkowski T, Alba E, Snyder R, Almel S, Rolski J, Munoz M, Moroose R, Hurvitz S, Baños A, Adewoye H, Hei J, Lindsay M, Rupin M,  Cabaribere D, Lemmerick Y, Mackey JR. Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Oncology. 2011 Apr;12(4):369-76. 
  10. Brufsky A, Hurvitz S, Perez E, Swamy R, O'Neill V, and Rugo HS. RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination with Chemotherapy for Second-Line Treatment of HER2-Negative Metastatic Breast Cancer. J Clin Oncol. 2011 Nov 10;29(32):4286-93. PMID: 21990397

In the News

Doctors Try to Avoid Doing Double Mastectomies - The Wall Street Journal

Note: News website links may expire without notice.


  • Super Doctors® Southern California, 2023
  • Top Doctors, Los Angeles Magazine, 2021, 2022, 2023
  • America’s Most Honored Doctors – Top 1%, 2020-2022
  • Castle Connolly Exceptional Women in Medicine, 2017-2022
  • Castle Connolly Top Doctors, California, 2014-2022
  • Southern California Super Doctors, 2010-2022
  • UCLA Health “100 in 100” Trailblazing Women Honoree, 2020
  • Southern California Top Doctors, 2020
  • Best Doctors in America,  2019-2020
  • Pasadena Magazine Top Doctor, 2017
  • Marni Levine Memorial Research Award 2008-2011, 2014, 2015
  • Top Women Southern California Super Doctors, 2011